iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Safety and Efficacy at 48 Weeks After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients With Risk Factors for TDF Use
 
  AASLD November 8-12, 2019, Boston, MA
Reported by Jules Levin
 
Maria Buti,1 Pietro Lampertico,2 Young-Suk Lim,3 Kosh Agarwal,4 Scott Fung,5 Tak Yin Owen Tsang,6 Magdy Elkashab,7 Jia-Horng Kao,8 Jose Luis Calleja-Panero,9 Mandana Khalili,10 Natarajan Ravendhran,11 Susanna Tan,12 John F. Flaherty,12 Anuj Gaggar,12 Audrey Lau,12 George Wu,12 Hie-Won Hann,13 Calvin Pan,14 Hyung Jun Kim,15 Patrick Kennedy,16 Henry Lik-Yuen Chan17
1Hospital Universitario Vall d'Hebron and Centro de Investigacion Biomedica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain; 2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy; 3Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 4Institute of Liver Studies, King's College Hospital, London, UK; 5Toronto Centre for Liver Disease, Toronto General Hospital, Toronto, Ontario, Canada; 6Princess Margaret Hospital, Hong Kong; 7Toronto Liver Centre, Toronto; 8Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan; 9Hospital Universitario Puerta de Hierro-Majadahonda, Spain; 10University of California San Francisco; 11Digestive Disease Associates, Catonsville, MD; 12Gilead Sciences, Inc., Foster City, CA; 13Thomas Jefferson University Hospital, Philadelphia, PA; 14Flushing, NY; 15Chung-Ang University College of Medicine, Seoul; 16Barts Health NHS Trust, London; 17The Chinese University of Hong Kong

1212191

1212192

1212193

1212194

1212195

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org